The crystal structure of the secreted aspartic proteinase 3 from Candida albicans and its complex with pepstatin A

Proteins: Structure, Function and Genetics

Volumn 68, Issue 3, 2007, Pages 738-748

  Borelli, Claudia ^a   Ruge, Elisabeth ^a   Schaller, Martin ^b   Monod, Michel ^c   Korting, Hans Christian ^a   Huber, Robert ^d   Maskos, Klaus ^d  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

Candida albicans; Inhibitor design; Pepstatin A; Secreted aspartic proteinase; X ray crystal structure

Indexed keywords

ASPARTIC PROTEINASE; ISOENZYME; PEPSTATIN; PROTEIN SAP 2; PROTEIN SAP 3; SECRETED ASPARTIC PROTEINASE 3; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ARTICLE; BINDING SITE; CANDIDA ALBICANS; COMPLEX FORMATION; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME ANALYSIS; ENZYME BINDING; ENZYME INHIBITOR INTERACTION; ENZYME SPECIFICITY; ENZYME STRUCTURE; FUNGAL GENE; FUNGAL VIRULENCE; INHIBITOR DESIGN; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; SAP GENE; X RAY;

ASPARTIC ENDOPEPTIDASES; CANDIDA ALBICANS; CRYSTALLOGRAPHY, X-RAY; FUNGAL PROTEINS; MODELS, MOLECULAR; PEPSTATINS; PICHIA; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY;

CANDIDA ALBICANS;

EID: 34447525518     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.21425     Document Type: Article

References (42)

1. Szecsi PB. The aspartic proteases. Scand J Clin Lab Invest Suppl 1992;210:5-22.
2. Hoegl L, Korting HC, Klebe G. Inhibitors of aspartic proteases in human diseases: molecular modeling comes of age. Pharmazie 1999;54:319-329.
3. Naglik JR, Challacombe SJ, Hube B. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 2003;67:400-428.
4. Schaller M, Korting HC, Borelli C, Hamm G, Hube B. Candida albicans-secreted aspartic proteinases modify the epithelial cytokine response in an in vitro model of vaginal candidiasis. Infect Immun 2005;73:2758-2765.
5. Schaller M, Schackert C, Korting HC, Januschke E, Hube B. Invasion of Candida albicans correlates with expression of secreted aspartic proteinases during experimental infection of human epider-mis. J Invest Dermatol 2000;114:712-717.
6. Naglik J, Albrecht A, Bader O, Hube B. Candida albicans proteinases and host/pathogen interactions. Cell Microbiol 2004;6:915-926.
7. Fusek M, Smith EA, Monod M, Dunn BM, Foundling SI. Extracellular aspartic proteinases from Candida albicans, Candida tropicalis, and Candida parapsilosis yeasts differ substantially in their specificities. Biochemistry 1994;33:9791-9799.
8. De Bernardis F, Cassone A, Sturtevant J, Calderone R. Expression of Candida albicans SAP1 and SAP2 in experimental vaginitis. Infect Immun 1995;63:1887-1892.
9. Naglik JR, Newport G, White TC, Fernandes-Naglik LL, Greenspan JS, Greenspan D, Sweet SP, Challacombe SJ, Agabian N. In vivo analysis of secreted aspartyl proteinase expression in human oral candidiasis. Infect Immun 1999;67:2482-2490.
10. Schaller M, Januschke E, Schackert C, Woerle B, Korting HC. Different isoforms of secreted aspartyl proteinases (Sap) are expressed by Candida albicans during oral and cutaneous candidosis in vivo. J Med Microbiol 2001;50:743-747.
11. Albrecht A, Felk A, Pichova I, Naglik JR, Schaller M, de Groot P, Maccallum D, Odds FC, Schafer W, Klis F, Monod M, Hube B. Glycosylphosphatidylinositol-anchored proteases of Candida albicans target proteins necessary for both cellular processes and host-pathogen interactions. J Biol Chem 2006;281:688-694.
12. Taylor BN, Hannemann H, Sehnal M, Biesemeier A, Schweizer A, Rollinghoff M, Schroppel K. Induction of SAP7 correlates with virulence in an intravenous infection model of candidiasis but not in a vaginal infection model in mice. Infect Immun 2005;73:7061-7063.
13. Stewart K, Abad-Zapatero C. Candida proteases and their inhibition: prospects for antifungal therapy. Curr Med Chem 2001;8:941-948.
14. Cutfield S, Marshall C, Moody P, Sullivan P, Cutfield J. Crystallization of inhibited aspartic proteinase from Candida albicans. J Mol Biol 1993;234:1266-1269.
15. Abad-Zapatero C, Goldman R, Muchmore SW, Hutchins C, Stewart K, Navaza J, Payne CD, Ray TL. Structure of a secreted aspartic protease from C. albicans complexed with a potent inhibitor: implications for the design of antifungal agents. Protein Sci 1996;5:640-652.
16. Cutfield SM, Dodson EJ, Anderson BF, Moody PC, Marshall CJ, Sullivan PA, Cutfield JF. The crystal structure of a major secreted aspartic proteinase from Candida albicans in complexes with two inhibitors. Structure 1995;3:1261-1271.
17. Cannon RD, Timberlake WE, Gow NA, Bailey D, Brown A, Gooday GW, Hube B, Monod M, Nombela C, Navarro F, Pérez R, Sánchez M, Pla J. Molecular biological and biochemical aspects of fungal dimorphism. J Med Vet Mycol 1994;32 (Suppl 1):53-64.
18. Hube B, Monod M, Schofield DA, Brown AJ, Gow NA. Expression of seven members of the gene family encoding secretory aspartyl proteinases in Candida albicans. Mol Microbiol 1994;14:87-99.
19. White TC, Agabian N. Candida albicans secreted aspartyl proteinases: isoenzyme pattern is determined by cell type, and levels are determined by environmental factors. J Bacteriol 1995;177:5215-5221.
20. Abad-Zapatero C, Goldman R, Muchmore SW, Hutchins C, Oie T, Stewart K, Cutfield SM, Cutfield JF, Foundling SI, Ray TL. Structure of secreted aspartic proteinases from Candida. Implications for the design of antifungal agents. Adv Exp Med Biol 1998;436:297-313.
21. Umezawa H, Aoyagi T, Morishima H, Matsuzaki M, Hamada M. Pepstatin, a new pepsin inhibitor produced by Actinomycetes. J Antibiot (Tokyo) 1970;23:259-262.
22. Borg-von Zepelin M, Beggah S, Boggian K, Sanglard D, Monod M. The expression of the secreted aspartyl proteinases Sap4 to Sap6 from Candida albicans in murine macrophages. Mol Microbiol 1998;28:543-554.
23. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;15:680-685.
24. Otwinowski Z, Minor W. DENZO: a film processing program for macromolecular crystallography. New Haven, CT: Yale University; 1993.
25. Kleywegt GJ, Jones TA. Efficient rebuilding of protein structures. Acta CrystallogrSect D: Biol Crystallogr 1996;52:829-832.
26. Vagin A, Teplyakov A. An approach to multi-copy search in molecular replacement. Acta CrystallogrSect D: Biol Crystallogr 2000;56:1622-1624.
27. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW. Crystallography and NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr-Sect D: Biol Crystallogr 1998;54:905-921.
28. Laskowski R, Macarthur M, Moss D, Thornton J. PROCHEK-a program to check the stereochemical quality of protein structures. J Appl Crystallogr 1993;26:283-291.
29. Ramachandran GN, Sasisekharan V. Conformation of polypeptides and proteins. Adv Protein Chem 1968;23:283-437.
30. DeLano WL. PyMOL reference manual. San Carlos, CA: DeLano Scientific LLC; 2006.
31. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22:4673-4680.
32. Davies DR. The structure and function of the aspartic proteinases. Annu Rev Biophys Biophys Chem 1990;19:189-215.
33. Sielecki AR, Fedorov AA, Boodhoo A, Andreeva NS, James MN. Molecular and crystal structures of monoclinic porcine pepsin refined at 1.8 Å resolution. J Mol Biol 1990;214:143-170.
34. Stewart K, Goldman R, Abad-Zapatero C. The secreted proteinases from Candida: challenges for structure-aided drug design. In: Dunn B, editor. Proteases of infectious agents. San Diego, CA: Academic Press; 1999. pp 117-138.
35. Dhanaraj V, Dealwis CG, Frazao C, Badasso M, Sibanda BL, Tickle IJ, Cooper JB, Driessen HP, Newman M, Aguilar C, Wood SP, Blundell TL, Hobert PM, Geoghegan KF, Ammirati MJ, Danley DE, O'Connor BA, Hoover DJ. X-ray analyses of peptide-inhibitor complexes define the structural basis of specificity for human and mouse renins. Nature 1992;357:466-472.
36. Metcalf P, Fusek M. Two crystal structures for cathepsin D: the lysosomal targeting signal and active site. EMBO J 1993;12:1293-1302.
37. James MN, Sielecki A, Salituro F, Rich DH, Hofmann T. Conformational flexibility in the active sites of aspartyl proteinases revealed by a pepstatin fragment binding to penicillopepsin. Proc Natl Acad Sci USA 1982;79:6137-6141.
38. Suguna K, Padlan EA, Bott R, Boger J, Parris KD, Davies DR. Structures of complexes of rhizopuspepsin with pepstatin and other statine-containing inhibitors. Proteins 1992;13:195-205.
39. Lowther WT, Majer P, Dunn BM. Engineering the substrate specificity of rhizopuspepsin: the role of Asp 77 of fungal aspartic proteinases in facilitating the cleavage of oligopeptide substrates with lysine in P1. Protein Sci 1995;4:689-702.
40. Koelsch G, Tang J, Loy JA, Monod M, Jackson K, Foundling SI, Lin X. Enzymic characteristics of secreted aspartic proteases of Candida albicans. Biochim Biophys Acta 2000;1480:117-131.
41. Capobianco JO, Lerner CG, Goldman RC. Application of a fluorogenic substrate in the assay of proteolytic activity and in the discovery of a potent inhibitor of Candida albicans aspartic proteinase. Anal Biochem 1992;204:96-102.
42. Fujinaga M, Chernaia MM, Tarasova NI, Mosimann SC, James MN. Crystal structure of human pepsin and its complex with pepstatin. Protein Sci 1995;4:960-972.